# Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens

> **NCT00204516** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital Tuebingen** · enrollment: 31 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** mRNA coding for melanoma associated antigens
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT00204516
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2011-08
- **Final completion:** 2012-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2013-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00204516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00204516, "Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00204516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*